Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis

Journal of the American Society of Nephrology

Volumn 25, Issue 5, 2014, Pages 1013-1027

  Scarpellini, Alessandra ^a   Huang, Linghong ^b   Burhan, Izhar ^a   Schroeder, Nina ^a   Funck, Muriel ^a   Johnson, Timothy S ^b   Verderio, Elisabetta A M ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; BUPRENORPHINE; COLLAGEN; CREATININE; HYDROXYPROLINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SYNDECAN 4; TRANSFORMING GROWTH FACTOR BETA1; ARISTOLOCHIC ACID I; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SDC4 PROTEIN, MOUSE; TGFB1 PROTEIN, MOUSE;

ANALGESIA; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL SURFACE; CHRONIC KIDNEY DISEASE; CREATININE URINE LEVEL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GLOMERULUS BASEMENT MEMBRANE; HYDROXYPROLINE URINE LEVEL; IMMUNODETECTION; IMMUNOFLUORESCENCE; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INTERSTITIUM; KIDNEY SCAR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RENAL PROTECTION; SCAR FORMATION; TUBULOINTERSTITIAL FIBROSIS; URETER OBSTRUCTION; ANIMAL; C57BL MOUSE; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; FIBROSIS; GENETICS; INTERSTITIAL NEPHRITIS; KNOCKOUT MOUSE; METABOLISM; NEPHROSCLEROSIS; PATHOLOGY; PHYSIOLOGY; TUBULOINTERSTITIAL NEPHRITIS AND UVEITIS; UVEITIS;

ANIMALS; ARISTOLOCHIC ACIDS; FIBROSIS; GTP-BINDING PROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEPHRITIS, INTERSTITIAL; NEPHROSCLEROSIS; RENAL INSUFFICIENCY, CHRONIC; SYNDECAN-4; TRANSFORMING GROWTH FACTOR BETA1; TRANSGLUTAMINASES; URETERAL OBSTRUCTION; UVEITIS;

EID: 84906540104     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013050563     Document Type: Article

References (54)

1. Johnson TS, El-Koraie AF, Skill NJ, Baddour NM, El Nahas AM, Njloma M, Adam AG, Griffin M: Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 14: 2052-2062, 2003
2. Johnson TS, FisherM,Haylor JL,Hau Z, SkillNJ, Jones R, Saint R,Coutts I, Vickers ME, El Nahas AM, Griffin M: Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 18: 3078-3088, 2007
3. Johnson TS, Haylor JL, Thomas GL, Fisher M, El Nahas AM: Matrix metalloproteinases and their inhibitions in experimental renal scarring. Exp Nephrol 10: 182-195, 2002
4. Skill NJ, GriffinM, El Nahas AM, Sanai T, Haylor JL, FisherM, Jamie MF, Mould NN, Johnson TS: Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications. Lab Invest 81: 705-716, 2001
5. Verderio EA, Johnson TS, Griffin M: Transglutaminases in wound healing and inflammation. Prog Exp Tumor Res 38: 89-114, 2005
6. Nunes I, Gleizes PE, Metz CN, Rifkin DB: Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 136: 1151-1163, 1997
7. Oh K, Park HB, ByounOJ, ShinDM, Jeong EM, KimYW, KimYS,Melino G, Kim IG, Lee DS: Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treatedmice. J Exp Med 208: 1707-1719, 2011
8. Shweke N, Boulos N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, Chatziantoniou C, Ronco P, Boffa JJ: Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 173: 631-642, 2008
9. Kojima S, Nara K, Rifkin DB: Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 121: 439-448, 1993
10. Lorand L, Graham RM: Transglutaminases: Crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4: 140-156, 2003
11. Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, Meguid El Nahas A: The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. J Clin Invest 99: 2950-2960, 1997
12. Johnson TS, Skill NJ, El Nahas AM, Oldroyd SD, Thomas GL, Douthwaite JA, Haylor JL, Griffin M: Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol 10: 2146-2157, 1999
13. El Nahas AM, Abo-Zenah H, Skill NJ, Bex S,Wild G, GriffinM, Johnson TS: Elevated epsilon-(gamma-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clin Pract 97: c108-c117, 2004
14. Mirza A, Liu SL, Frizell E, Zhu J, Maddukuri S, Martinez J, Davies P, Schwarting R, Norton P, Zern MA: A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol 272: G281-G288, 1997
15. Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier M, Vuitton DA, Ricard-Blum S: Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. JHepatol 35: 367-375, 2001
16. Johnson TS, Abo-Zenah H, Skill JN, Bex S,Wild G, Brown CB, GriffinM, El Nahas AM: Tissue transglutaminase: a mediator and predictor of chronic allograft nephropathy? Transplantation 77: 1667-1675, 2004
17. Verderio EA, Telci D, Okoye A, Melino G, Griffin M: A novel RGDindependent cel adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J Biol Chem 278: 42604-42614, 2003
18. Telci D,Wang Z, Li X, Verderio EA, Humphries MJ, Baccarini M, Basaga H, Griffin M: Fibronectin-tissue transglutaminase matrix rescues RGDimpaired cell adhesion through syndecan-4 and beta1 integrin cosignaling. J Biol Chem283: 20937-20947, 2008
19. Belkin AM: Extracellular TG2: Emerging functions and regulation. FEBS J 278: 4704-4716, 2011
20. Badarau E, Collighan RJ, Griffin M: Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids 44: 119-127, 2013
21. Zemskov EA, Mikhailenko I, Hsia RC, Zaritskaya L, Belkin AM: Unconventional secretion of tissue transglutaminase involves phospholipiddependent delivery into recycling endosomes. PLoS ONE 6: e19414, 2011
22. Chou CY, Streets AJ, Watson PF, Huang L, Verderio EA, Johnson TS: A crucial sequence for transglutaminase type 2 extracellular trafficking in renal tubular epithelial cells lies in its N-terminal beta-sandwich domain. J Biol Chem 286: 27825-27835, 2011
23. Scarpellini A, Germack R, Lortat-Jacob H, Muramatsu T, Billett E, Johnson T, Verderio EA: Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2. J Biol Chem 284: 18411-18423, 2009
24. Lortat-Jacob H, Burhan I, Scarpellini A, Thomas A, Imberty A, Vivès RR, Johnson T, Gutierrez A, Verderio EA: Transglutaminase-2 interaction with heparin: Identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix. J Biol Chem 287: 18005-18017, 2012
25. Zehe C, Engling A, Wegehingel S, Schäfer T, Nickel W: Cell-surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2. Proc Natl Acad Sci U S A 103: 15479-15484, 2006
26. Clayton A, Thomas J, Thomas GJ, Davies M, Steadman R: Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int 59: 2084-2094, 2001
27. Yung S, Woods A, Chan TM, Davies M, Williams JD, Couchman JR: Syndecan-4 up-regulation in proliferative renal disease is related to microfilament organization. FASEB J 15: 1631-1633, 2001
28. FanQ, Shike T, Shigihara T, TanimotoM, Gohda T,Makita Y, Wang LN, Horikoshi S, Tomino Y: Gene expression profile in diabetic KK/Tamice. Kidney Int 64: 1978-1985, 2003
29. Ishiguro K, Kadomatsu K, Kojima T,Muramatsu H, Tsuzuki S, Nakamura E, Kusugami K, Saito H, Muramatsu T: Syndecan-4 deficiency impairs focal adhesion formation only under restricted conditions. J Biol Chem 275: 5249-5252, 2000
30. Vielhauer V, Anders HJ, Mack M, Cihak J, Strutz F, Stangassinger M, Luckow B, Gröne HJ, Schlöndorff D: Obstructive nephropathy in the mouse: Progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation ofCCchemokine receptor 2-and 5-positive leukocytes. J Am Soc Nephrol 12: 1173-1187, 2001
31. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-LanckmanMM, Vanherweghem JL: Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 13: 431-436, 2002
32. Huang L, Scarpellini A, Funck M, Verderio EA, Johnson TS: Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology. Nephron Extra 3: 12-29, 2013
33. Verderio E, Gaudry C, Gross S, Smith C, Downes S, Griffin M: Regulation of cell surface tissue transglutaminase: effects on matrix storage of latent transforming growth factor-beta binding protein-1. J Histochem Cytochem 47: 1417-1432, 1999
34. Huang L, Haylor JL, Fisher M, Hau Z, El Nahas AM, Griffin M, Johnson TS: Do changes in transglutaminase activity alter latent transforming growth factor beta activation in experimental diabetic nephropathy? Nephrol Dial Transplant 25: 3897-3910, 2010
35. Manders EMM, Verbeek FJ, Aten JA:Measurement of colocalization of objects in dual-color confocal images. J Microsc 169: 375-382, 1993
36. Sarrazin S, LamannaWC, Esko JD:Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3: 3, 2011
37. Rienstra H, Katta K, Celie JW, van Goor H, Navis G, van den Born J, Hillebrands JL: Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats. PLoS ONE 5: e9095, 2010
38. Abe M, Harpel JG,Metz CN, Nunes I, Loskutoff DJ, Rifkin DB: An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216: 276-284, 1994
39. Chen L, Klass C, Woods A: Syndecan-2 regulates transforming growth factor-beta signaling. J Biol Chem 279: 15715-15718, 2004
40. Verderio EA, Scarpellini A, Johnson TS: Novel interactions of TG2 with heparan sulfate proteoglycans: Reflection on physiological implications. Amino Acids 36: 671-677, 2009
41. Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A: Chronic renal insufficiency in children: The 2001 Annual Report of the NAPRTCS. Pediatr Nephrol 18: 796-804, 2003
42. Schainuck LI, Striker GE, Cutler RE, Benditt EP: Structural-functional correlations in renal disease. II. The correlations. Hum Pathol 1: 631-641, 1970
43. FragiadakiM, Witherden AS, Kaneko T, Sonnylal S, Pusey CD, Bou-GhariosG, Mason RM: Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo. Matrix Biol 30: 396-403, 2011
44. Echtermeyer F, Streit M, Wilcox-Adelman S, Saoncella S, Denhez F, Detmar M, Goetinck P: Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 107: R9-R14, 2001
45. Bishop JR, Schuksz M, Esko JD: Heparan sulphate proteoglycans finetune mammalian physiology. Nature 446: 1030-1037, 2007
46. Cevikbas F, Schaefer L, Uhlig P, Robenek H, Theilmeier G, Echtermeyer F, Bruckner P: Unilateral nephrectomy leads to up-regulation of syndecan-2-and TGF-beta-mediated glomerulosclerosis in syndecan-4 deficient male mice. Matrix Biol 27: 42-52, 2008
47. Wang Z, Collighan RJ, Pytel K, Rathbone DL, Li X, Griffin M: Characterization of heparin-binding site of tissue transglutaminase: Its importance in cell surface targeting, matrix deposition, and cell signaling. J Biol Chem287: 13063-13083, 2012
48. Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A: Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 167: 1699-1711, 2005
49. Ishiguro K, Kadomatsu K, Kojima T,Muramatsu H, IwaseM, Yoshikai Y, Yanada M, Yamamoto K, Matsushita T, NishimuraM, Kusugami K, Saito H, Muramatsu T: Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem 276: 47483-47488, 2001
50. Huang L, Johnson TS: Development of a chronic kidney disease model in C57BL/6 mice that is relevant to human disease. Presented at the BRS/RA Conference, Birmingham, United Kingdom, June 6, 2011.
51. Annes JP, Munger JS, Rifkin DB: Making sense of latent TGFbeta activation. J Cell Sci 116: 217-224, 2003
52. Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, OgawaM, YoshidaM, Kondo S, Satoh N, Ueda S: Acute nephrotoxicity of aristolochic acids in mice. J Pharm Pharmacol 56: 221-229, 2004
53. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH: Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273: 12960-12966, 1998
54. Huang L, Haylor JL, Hau Z, Jones RA, Vickers ME, Wagner B, GriffinM, Saint RE, Coutts IGC, Meguid El Nahas A, Johnson TS: Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int 76: 383-394, 2009